Sinocelltech Group Ltd 688520.SS

Last Updated: May 15, 12:00 AM·SSE

Sinocelltech Group Ltd

Sinocelltech Group Ltd. Stock Analysis 688520.SS

China Health Care Mid Cap
Sinocelltech Group Ltd. engages in the research and development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company is headquartered in Beijing, Beijing and currently employs 2,200 full-time employees. The company went IPO on 2020-06-22. The firm's products include SCT800, SCT400, SCT630, SCT510, SCTV01 and others. The firm's products are mainly used in multiple treatment and prevention fields such as malignant tumors, autoimmune diseases, infectious diseases and genetic diseases. The firm mainly operates its businesses in the domestic market.
Read More
Lock image
crown-icon

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.